Tumor necrosis factor inhibitor (anti-TNF) treatment is effective at improving both muscle and skin involvement in children with juvenile dermatomyositis (JDM), according to data presented at the EULAR 2016 conference. These findings bring new hope to JDM patients who have failed multiple drug treatments and who, as a result, have a greater risk of painful complications and premature death.

 

Click here for more.